Gastroenterology

Stay updated with the latest healthcare breakthroughs, including data from DDW and a new podcast episode.

Fukami, MD, discusses how first-line ESD may offer both survival and cost advantages over esophagectomy for EEC in the United States.

Despite a growing armamentarium of approved IBD therapies, outcomes remain suboptimal. Rubin explains how earlier treatment and smarter optimization can close the gap.

Laurent Peyrin-Biroulet, MD, PhD, breaks down FUZION data demonstrating meaningful fistula healing with guselkumab in Crohn’s disease patients with perianal disease.

Routine depression and anxiety screening in IBD clinics was tied to significantly more referrals and sustained follow-up with psychogastroenterology services

1-year results from ASPIRE-CD suggest risankizumab (Skyrizi) improves HRQL, well-being, and treatment satisfaction in adults with Crohn's Disease.

COBRA findings suggest 1 day of antibiotic treatment is preferred in acute cholangitis after adequate biliary drainage compared to longer guidelines.

Edward Barnes, MD, MPH, explains mirikizumab’s strong remission and durable response in Crohn’s disease patients after anti-TNF failure, supporting second-line use.

Maria Abreu, MD, breaks down efficacy and safety data for dual-target co-antibody JNJ-4804, offering a potential new option for heavily pretreated UC patients.

The phase 3 FUZION trial found guselkumab achieved increased fistula remission rates than placebo in perianal fistulizing Crohn's disease.

Updated results from the NordICC trial build upon previous 10 year findings and shed further light on once-only colonoscopy as a primary screening modality.

JNJ-4804 phase 2b results showed higher week-48 remission rates in refractory ulcerative colitis and Crohn disease.

Phase 4 dupilumab data show improvements in esophageal distensibility and disease-related structural changes and inflammation in the esophagus in EoE.

Long-term LUCENT-3 data show mirikizumab sustained disease clearance in ulcerative colitis through 4 years of treatment.

Stephanie Gold, MD, explains prospective IBD-Metabolic Clinic data show GLP-1 RAs are safe and effective for weight management in IBD, with added benefits for bowel function and fatigue.

New research underscores the risks and daily burden of TPN in SBS, with focus shifting toward reducing dependence and complications.

Gil Melmed, MD, breaks down real-world data showing risankizumab has the lowest switch rates in Crohn’s over 24 months, highlighting strong persistence vs other biologics.

Murray breaks down what gastroenterologists need to know about celiac disease diagnosis and management.

Marla Dubinsky, MD, explains LIBERTY post hoc data showing SC infliximab 240 mg recaptured clinical response within 8 weeks in CD and UC patients following a drug holiday.

Laurie Keefer, PhD, makes the case for integrating mental health, social determinants, and brain-gut behavior therapies into routine GI care.

Anjali Byale, MD, reviews data supporting EUS-guided procedures as first-line options for high-risk patients with cholecystitis or malignant gastric outlet obstruction.

Wu describes her research linking low food access and food insecurity to higher childhood obesity risk, highlighting the need for early, multilevel prevention strategies.

Shah describes the science and real-world use of gluten sensors, with insights on how these tools may support patients with celiac disease without replacing standard care.

IBS care is evolving with personalized, multimodal strategies, but gaps in access, education, and real-world outcomes continue to impact patients’ lives